Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

1.50
+0.13009.49%
Pre-market: 1.560.0600+4.00%05:28 EST
Volume:411.37K
Turnover:610.60K
Market Cap:32.80M
PE:-0.16
High:1.53
Open:1.38
Low:1.38
Close:1.37
52wk High:8.08
52wk Low:1.17
Shares:21.87M
Float Shares:19.10M
Volume Ratio:0.89
T/O Rate:2.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.2900
EPS(LYR):-23.5105
ROE:-1766.94%
ROA:-67.31%
PB:-0.37
PE(LYR):-0.06

Loading ...

BioXcel Therapeutics führt neue Bonusvereinbarungen für Führungskräfte ein

Reuters
·
Feb 07

Rigel Pharmaceuticals beruft Michael P. Miller in den Vorstand

Reuters
·
Feb 03

BUZZ-BioXcel seeks FDA nod for at‑home agitation treatment; shares fall

Reuters
·
Jan 20

BioXcel Therapeutics Submits sNDA to FDA for IGALMI Label Expansion to At-Home Use

Reuters
·
Jan 20

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Igalmi® Label Expansion in the at-Home Setting

THOMSON REUTERS
·
Jan 20

BioXcel Therapeutics Inc: Submission Timeline Supports Potential Approval of Igalmi Label Expansion as Early as Year-End 2026

THOMSON REUTERS
·
Jan 20

BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer

Reuters
·
Jan 13

BioXcel Therapeutics Inc - to Submit Snda This Month for Igalmi at-Home Use - SEC Filing

THOMSON REUTERS
·
Jan 12

BioXcel Therapeutics Plans sNDA Submission for IGALMI At-Home Use

Reuters
·
Jan 12

BioXcel Therapeutics Plans sNDA Submission Seeking FDA Approval for At-Home Use of IGALMI

Reuters
·
Jan 07

BioXcel Therapeutics Planning to Submit Snda This Month Seeking FDA Approval for at-Home Use of Igalmi®

THOMSON REUTERS
·
Jan 07

BioXcel Therapeutics Inc. held annual shareholder meeting

Reuters
·
Dec 16, 2025

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI) and Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Nov 13, 2025

BioXcel Therapeutics Q3 revenue misses analyst expectations

Reuters
·
Nov 12, 2025

BRIEF-BioXcel Therapeutics Q3 Basic EPS USD -2.18 Vs. IBES Estimate USD -1.24

Reuters
·
Nov 12, 2025

BioXcel Therapeutics Q3 Basic EPS USD -2.18 VS. Ibes Estimate USD -1.24

THOMSON REUTERS
·
Nov 12, 2025

BioXcel Therapeutics Q3 Revenue USD 98 Thousand VS. Ibes Estimate USD 216 Thousand

THOMSON REUTERS
·
Nov 12, 2025

BioXcel Therapeutics Reports Phase 3 Study Results on BXCL501 for Agitation in Bipolar Disorder and Schizophrenia at Home

Reuters
·
Nov 10, 2025

BioXcel Therapeutics Inc. Announces Date for 2025 Annual Stockholder Meeting

Reuters
·
Nov 01, 2025

BRIEF-BioXcel Therapeutics Inc - Updates On sNDA Submission For IGALMI Label Expansion - SEC Filing

Reuters
·
Oct 30, 2025